Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 2/2010

01-06-2010 | Preclinical study

A unique RNA-directed nucleoside analog is cytotoxic to breast cancer cells and depletes cyclin E levels

Authors: Christine M. Stellrecht, Mary Ayres, Rishi Arya, Varsha Gandhi

Published in: Breast Cancer Research and Treatment | Issue 2/2010

Login to get access

Abstract

In contrast to deoxyribose or arabinose containing nucleoside analogs that are currently established for cancer therapeutics, 8-chloro-adenosine (8-Cl-Ado) possesses a ribose sugar. This unique nucleoside analog is RNA-directed and is in a phase I clinical trial for hematological malignancies. RNA-directed therapies are effective for the treatment of many malignancies as their activities are primarily aimed at short-lived transcripts, which are typically encoded by genes that promote the growth and survival of tumor cells such as cyclin E in breast cancer. Based on this, we hypothesized that 8-Cl-Ado, a transcription inhibitor, will be effective for the treatment of breast cancer cells. The metabolism of 8-Cl-Ado and the effect on ATP in the breast cancer cell lines MCF-7 and BT-474 were measured using HPLC analysis. In these cells, 8-Cl-Ado was effectively taken up, converted to its cytotoxic metabolite, 8-Cl-ATP, and depleted the endogenous ATP levels. This in turn led to an inhibition of RNA synthesis. The RNA synthesis inhibition was associated with a depletion of cyclin E expression, which is indicative of a diminished tumorigenic phenotype. The final outcome of 8-Cl-Ado treatment of the breast cancer cells was growth inhibition due to an induction of apoptosis and a loss of clonogenic survival. These results indicate that 8-Cl-Ado, which is currently in clinic for hematological malignancies, may be an effective agent for the treatment of breast cancer.
Literature
1.
Stellrecht CM, Chen LS, Gandhi V (2005) Inhibition of oncogene expression by RNA-directed agents. In: Gandhi V (ed) Transcription as a target for cancer therapeutics AACR educational book. American Association for Cancer Research, Philadelphia, pp 338–343
2.
Derheimer FA, Chang CW, Ljungman M (2005) Transcription inhibition: a potential strategy for cancer therapeutics. Eur J Cancer 41:2569–2576CrossRefPubMed
3.
Bakheet T, Williams BR, Khabar KS (2003) ARED 2.0: an update of AU-rich element mRNA database. Nucleic Acids Res 31:421–423CrossRefPubMed
4.
Lam LT, Pickeral OK, Peng AC et al. (2001) Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol. Genome Biol 2:research0041.0041-research0041.0011
5.
6.
7.
Weinstein B (2008) Relevance of the concept of oncogene addiction to hormonal carcinogenesis and molecular targeting in cancer prevention and therapy. Adv Exp Med Biol 617:3–13CrossRefPubMed
8.
Certo M, Moore Vdel G, Nishino M et al (2006) Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell 9:351–365CrossRefPubMed
9.
10.
Chen R, Keating MJ, Gandhi V, Plunkett W (2005) Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death. Blood 106:2513–2519CrossRefPubMed
11.
Gojo I, Zhang B, Fenton RG (2002) The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1. Clin Cancer Res 8:3527–3538PubMed
12.
Pepper C, Thomas A, Hoy T, Fegan C, Bentley P (2001) Flavopiridol circumvents Bcl-2 family mediated inhibition of apoptosis and drug resistance in B-cell chronic lymphocytic leukaemia. Br J Haematol 114:70–77CrossRefPubMed
13.
14.
Raje N, Kumar S, Hideshima T et al (2005) Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma. Blood 106:1042–1047CrossRefPubMed
15.
MacCallum DE, Melville J, Frame S et al (2005) Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1. Cancer Res 65:5399–5407CrossRefPubMed
16.
Shapiro GI (2006) Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 24:1770–1783CrossRefPubMed
17.
18.
Langeveld CH, Jongenelen CA, Theeuwes JW et al (1997) The antiproliferative effect of 8-chloro-adenosine, an active metabolite of 8-chloro-cyclic adenosine monophosphate, and disturbances in nucleic acid synthesis and cell cycle kinetics. Biochem Pharmacol 53:141–148. doi:S0006-2952(96)00593-X[pii] CrossRefPubMed
19.
Langeveld CH, Jongenelen CA, Heimans JJ, Stoof JC (1992) 8-Chloro-cyclic adenosine monophosphate, a novel cyclic AMP analog that inhibits human glioma cell growth in concentrations that do not induce differentiation. Exp Neurol 117:196–203. doi:0014-4886(92)90127-C[pii] CrossRefPubMed
20.
Langeveld CH, Jongenelen CA, Heimans JJ, Stoof JC (1992) Growth inhibition of human glioma cells induced by 8-chloroadenosine, an active metabolite of 8-chloro cyclic adenosine 3′:5′-monophosphate. Cancer Res 52:3994–3999PubMed
21.
Gandhi V, Ayres M, Halgren RG et al (2001) 8-chloro-cAMP and 8-chloro-adenosine act by the same mechanism in multiple myeloma cells. Cancer Res 61:5474–5479PubMed
22.
Krett NL, Zell JL, Halgren RG et al (1997) Cyclic adenosine-3′, 5′-monophosphate-mediated cytotoxicity in steroid sensitive and resistant myeloma. Clin Cancer Res 3:1781–1787PubMed
23.
Halgren RG, Traynor AE, Pillay S et al (1998) 8Cl-cAMP cytotoxicity in both steroid sensitive and insensitive multiple myeloma cell lines is mediated by 8Cl-adenosine. Blood 92:2893–2898PubMed
24.
Zhu B, Zhang LH, Zhao YM, Cui JR, Strada SJ (2006) 8-chloroadenosine induced HL-60 cell growth inhibition, differentiation, and G(0)/G(1) arrest involves attenuated cyclin D1 and telomerase and up-regulated p21(WAF1/CIP1). J Cell Biochem 97:166–177CrossRefPubMed
25.
Carlson CC, Chinery R, Burnham LL, Dransfield DT (2000) 8-Cl-adenosine-induced inhibition of colorectal cancer growth in vitro and in vivo. Neoplasia 2:441–448CrossRefPubMed
26.
Zhang HY, Gu YY, Li ZG et al (2004) Exposure of human lung cancer cells to 8-chloro-adenosine induces G2/M arrest and mitotic catastrophe. Neoplasia 6:802–812CrossRefPubMed
27.
Stellrecht CM, Rodriguez CO Jr, Ayres M, Gandhi V (2003) RNA-directed actions of 8-chloro-adenosine in multiple myeloma cells. Cancer Res 63:7968–7974PubMed
28.
Chen LS, Sheppard TL (2004) Chain termination and inhibition of Saccharomyces cerevisiae poly(A) polymerase by C-8-modified ATP analogs. J Biol Chem 279:40405–40411CrossRefPubMed
29.
30.
Keyomarsi K, Pardee AB (1993) Redundant cyclin overexpression and gene amplification in breast cancer cells. Proc Natl Acad Sci U S A 90:1112–1116CrossRefPubMed
31.
Keyomarsi K, O’Leary N, Molnar G et al (1994) Cyclin E, a potential prognostic marker for breast cancer. Cancer Res 54:380–385PubMed
32.
Reed SI (2005) Deregulation of cyclin E in cancer. In: Reed SI (ed) The ubiquitin proteasome system: roles and targets in cancer AACR educational book. American Association for Cancer Research, Philadelphia, pp 53–56
33.
Keck JM, Summers MK, Tedesco D et al (2007) Cyclin E overexpression impairs progression through mitosis by inhibiting APCCdh1. J Cell Biol 178:371–385CrossRefPubMed
34.
Akli S, Zheng PJ, Multani AS et al (2004) Tumor-specific low molecular weight forms of cyclin E induce genomic instability and resistance to p21, p27, and antiestrogens in breast cancer. Cancer Res 64:3198–3208CrossRefPubMed
35.
Ekholm-Reed S, Mendez J, Tedesco D et al (2004) Deregulation of cyclin E in human cells interferes with prereplication complex assembly. J Cell Biol 165:789–800CrossRefPubMed
36.
Bagheri-Yarmand R, Keyomarsi K (2009) Overexpression of full length or low molecular weight of cyclin E leads to differential G2/M transition and mitotic defects through deregulation of cdc25c. AACR Meet Abstr 2009:2473
37.
Keyomarsi K, Tucker SL, Buchholz TA et al (2002) Cyclin E and survival in patients with breast cancer. N Engl J Med 347:1566–1575CrossRefPubMed
38.
Sieuwerts AM, Look MP, Meijer-van Gelder ME et al (2006) Which cyclin E prevails as prognostic marker for breast cancer? Results from a retrospective study involving 635 lymph node-negative breast cancer patients. Clin Cancer Res 12:3319–3328CrossRefPubMed
39.
Keyomarsi K, Tucker SL, Bedrosian I (2003) Cyclin E is a more powerful predictor of breast cancer outcome than proliferation. Nat Med 9:152CrossRefPubMed
40.
Wingate H, Bedrosian I, Akli S, Keyomarsi K (2003) The low molecular weight (LMW) isoforms of cyclin E deregulate the cell cycle of mammary epithelial cells. Cell cycle 2:461–466PubMed
41.
Wingate H, Zhang N, McGarhen MJ et al (2005) The tumor-specific hyperactive forms of cyclin E are resistant to inhibition by p21 and p27. J Biol Chem 280:15148–15157CrossRefPubMed
42.
Akli S, Van Pelt CS, Bui T et al (2007) Overexpression of the low molecular weight cyclin E in transgenic mice induces metastatic mammary carcinomas through the disruption of the ARF-p53 pathway. Cancer Res 67:7212–7222CrossRefPubMed
43.
Clurman BE, Sheaff RJ, Thress K, Groudine M, Roberts JM (1996) Turnover of cyclin E by the ubiquitin-proteasome pathway is regulated by cdk2 binding and cyclin phosphorylation. Genes Dev 10:1979–1990CrossRefPubMed
44.
Hapke DM, Stegmann AP, Mitchell BS (1996) Retroviral transfer of deoxycytidine kinase into tumor cell lines enhances nucleoside toxicity. Cancer Res 56:2343–2347PubMed
45.
46.
Shedden K, Townsend LB, Drach JC, Rosania GR (2003) A rational approach to personalized anticancer therapy: chemoinformatic analysis reveals mechanistic gene-drug associations. Pharm Res 20:843–847CrossRefPubMed
47.
Carlson CC, Burnham LL, Shanks RA, Dransfield DT (2001) 8-Cl-adenosine induces differentiation in LS174T cells. Dig Dis Sci 46:757–764CrossRefPubMed
48.
Van Lookeren Campagne MM, Villalba Diaz F, Jastorff B, Kessin RH (1991) 8-Chloroadenosine 3′, 5′-monophosphate inhibits the growth of Chinese hamster ovary and Molt-4 cells through its adenosine metabolite. Cancer Res 51:1600–1605PubMed
49.
Lu X, Errington J, Chen VJ et al (2001) Cellular ATP depletion by LY309887 as a predictor of growth inhibition in human tumor cell lines. Clin Cancer Res 6:271–277
50.
Jang JY, Choi Y, Jeon YK, Kim CW (2008) Suppression of adenine nucleotide translocase-2 by vector-based siRNA in human breast cancer cells induces apoptosis and inhibits tumor growth in vitro and in vivo. Breast Cancer Res 10:R11CrossRefPubMed
51.
Akli S, Keyomarsi K (2003) Cyclin E and its low molecular weight forms in human cancer and as targets for cancer therapy. Cancer Biol Ther 2:S38–S47PubMed
52.
Spruck CH, Won KA, Reed SI (1999) Deregulated cyclin E induces chromosome instability. Nature 401:297–300CrossRefPubMed
53.
Ma Y, Fiering S, Black C et al (2007) Transgenic cyclin E triggers dysplasia and multiple pulmonary adenocarcinomas. Proc Natl Acad Sci U S A 104:4089–4094CrossRefPubMed
54.
Sgambato A, Camerini A, Pani G et al (2003) Increased expression of cyclin E is associated with an increased resistance to doxorubicin in rat fibroblasts. Br J Cancer 88:1956–1962CrossRefPubMed
Metadata
Title
A unique RNA-directed nucleoside analog is cytotoxic to breast cancer cells and depletes cyclin E levels
Authors
Christine M. Stellrecht
Mary Ayres
Rishi Arya
Varsha Gandhi
Publication date
01-06-2010
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 2/2010
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-009-0481-3

Other articles of this Issue 2/2010

Breast Cancer Research and Treatment 2/2010 Go to the issue

Preclinical study

Clinical evaluation of chemotherapy response predictors developed from breast cancer cell lines

Epidemiology

Ki67: a time-varying biomarker of risk of breast cancer in atypical hyperplasia

Report

Low SAFB levels are associated with worse outcome in breast cancer patients

Clinical trial

Three versus six months of exercise training in breast cancer survivors

Clinical trial

Phase III randomized adjuvant study of tamoxifen alone versus sequential tamoxifen and anastrozole in Japanese postmenopausal women with hormone-responsive breast cancer: N-SAS BC03 study

Review

Conflict of interest in economic analyses of aromatase inhibitors in breast cancer: a systematic review
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits